S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:XBIO

Xenetic Biosciences (XBIO) Stock Price, News & Analysis

$3.77
-0.21 (-5.28%)
(As of 03/28/2024 ET)
Today's Range
$3.77
$3.90
50-Day Range
$3.27
$4.35
52-Week Range
$2.55
$5.97
Volume
3,449 shs
Average Volume
5,453 shs
Market Capitalization
$5.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.00

Xenetic Biosciences MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
941.7% Upside
$40.00 Price Target
Short Interest
Healthy
0.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.85mentions of Xenetic Biosciences in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.43) to ($0.82) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.67 out of 5 stars

XBIO stock logo

About Xenetic Biosciences Stock (NASDAQ:XBIO)

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

XBIO Stock Price History

XBIO Stock News Headlines

Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Xenetic Dips on Full-Year Results
Xenetic Biosciences reports FY results
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Xenetic Biosciences Inc XBIO
Xenetic Biosciences: Q3 Earnings Insights
MediciNova: Q3 Earnings Snapshot
XBIO Xenetic Biosciences, Inc.
XBIO.PH - | Stock Price & Latest News | Reuters
See More Headlines
Receive XBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2021
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:XBIO
Fax
N/A
Employees
4
Year Founded
2011

Price Target and Rating

Average Stock Price Target
$40.00
High Stock Price Target
$40.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+925.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-4,140,000.00
Net Margins
-162.84%
Pretax Margin
-162.79%

Debt

Sales & Book Value

Annual Sales
$2.54 million
Book Value
$6.36 per share

Miscellaneous

Free Float
1,402,000
Market Cap
$6.01 million
Optionable
Not Optionable
Beta
2.61

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Jeffrey F. Eisenberg (Age 53)
    CEO & Director
  • Mr. James F. Parslow (Age 54)
    CFO, COO & Corp. Sec.
  • Dr. Curtis A. Lockshin (Age 59)
    Chief Scientific Officer

XBIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Xenetic Biosciences stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenetic Biosciences in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" XBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XBIO, but not buy additional shares or sell existing shares.
View XBIO analyst ratings
or view top-rated stocks.

What is Xenetic Biosciences' stock price target for 2024?

1 brokerages have issued 12-month target prices for Xenetic Biosciences' shares. Their XBIO share price targets range from $40.00 to $40.00. On average, they predict the company's stock price to reach $40.00 in the next twelve months. This suggests a possible upside of 941.7% from the stock's current price.
View analysts price targets for XBIO
or view top-rated stocks among Wall Street analysts.

How have XBIO shares performed in 2024?

Xenetic Biosciences' stock was trading at $3.45 at the beginning of 2024. Since then, XBIO shares have increased by 11.3% and is now trading at $3.84.
View the best growth stocks for 2024 here
.

Are investors shorting Xenetic Biosciences?

Xenetic Biosciences saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 2,200 shares, a drop of 74.7% from the February 29th total of 8,700 shares. Based on an average daily volume of 5,300 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.2% of the company's shares are sold short.
View Xenetic Biosciences' Short Interest
.

When is Xenetic Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our XBIO earnings forecast
.

How were Xenetic Biosciences' earnings last quarter?

Xenetic Biosciences Inc (NASDAQ:XBIO) released its quarterly earnings data on Thursday, November, 11th. The company reported ($1.30) earnings per share for the quarter, missing analysts' consensus estimates of ($1.20) by $0.10. The firm earned $0.35 million during the quarter, compared to the consensus estimate of $0.20 million. Xenetic Biosciences had a negative net margin of 162.84% and a negative trailing twelve-month return on equity of 36.43%.

When did Xenetic Biosciences' stock split?

Xenetic Biosciences shares reverse split before market open on Monday, May 15th 2023. The 1-10 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Xenetic Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenetic Biosciences investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Biocept (BIOC), Trevena (TRVN), TherapeuticsMD (TXMD), T2 Biosystems (TTOO), Vaxart (VXRT), Aytu BioPharma (AYTU) and Co-Diagnostics (CODX).

Who are Xenetic Biosciences' major shareholders?

Xenetic Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Xenetic Biosciences?

Shares of XBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XBIO) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners